An Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Clinical Trial Type: Colon
MERCK (KeyVibe-008)
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center
Merck MK-7339-003 (LYNK-003)
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) Principal Investigator: Dr. Sreenivasa Chandana For more information on this
Merck MK7902-015 (LEAP015)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK 7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) PI: Dr. Chandana Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton
MERCK MK7864A-007
A Randomized, Double-Blind, Phase 3 Study of MK-7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer PI: Dr Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion
PAL-E602-001 (Palleon)
Description: A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers Target Patient Population: Melanoma, Ovarian, Non Small Cell Lung Cancer, Colorectal and Pancreatic cancers Study Design: Drug is given
SY-5609-101 (Syros)
SY-5609-101 (Syros) Description: A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select Advanced Solid Tumors Target Patient Population: Metastatic breast cancer, ovarian, lung, colorectal or any malignancy with mutation of RB1, CDKN1A/CDKN2A, amplification of CCNE1, CCND1, CCND2, CDK4 or CDK6); in combination with gemcitabine or gemcitabine/nab-paclitaxel in
Sym024-01 (Symphogen)
Description: A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies Target Patient Population: NSCLC (Adeno), Pancreatic, Cholangiocarcinoma, Metastatic Colorectal, Gastric, Esophageal, Mesothelioma and Squamous cell Head & Neck Study Design: Both Drugs
TH1902-CTR-0001 (Theratechnologies, Inc.)
Description: A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer and Pancreatic Cancer Target Patient Population: Currently in Dose Escalation with all Solid Tumors. Study Design: Drug is administered IV every 3 weeks.